verona
pharma
plc
update
aim
delisting
london
raleigh
globe
newswire
verona
pharma
plc
aim
vrp
nasdaq
vrna
verona
pharma
company
provides
update
regards
intended
delisting
cancellation
ordinary
shares
trading
aim
announced
september
previously
announced
last
day
trading
company
ordinary
shares
aim
october
proposed
aim
delisting
effective
london
time
october
verona
pharma
retain
listing
adss
nasdaq
global
market
ticker
symbol
vrna
following
aim
delisting
shares
tradeable
nasdaq
information
process
convert
ordinary
shares
adss
provided
announcement
published
company
september
also
available
company
website
https
investors
conversion
made
time
including
aim
delisting
however
holders
ordinary
shares
reminded
conversion
made
prior
aim
delisting
october
ads
conversion
fees
us
per
ads
ordinarily
charged
company
depositary
citibank
waived
uk
stamp
duty
rate
per
cent
market
value
shares
incurred
following
aim
delisting
singer
cease
act
nominated
adviser
broker
company
capitalised
terms
used
defined
announcement
included
announcement
made
september
information
please
contact
verona
pharma
plc
tel
david
zaccardelli
chief
executive
officer
info
victoria
stewart
director
communications
singer
nominated
adviser
uk
broker
tel
aubrey
powell
george
tzimas
iqra
amin
corporate
finance
tom
salvesen
corporate
broking
verona
pharma
verona
pharma
biopharmaceutical
company
focused
developing
commercializing
innovative
therapies
treatment
respiratory
diseases
significant
unmet
medical
needs
successfully
developed
approved
verona
pharma
product
candidate
ensifentrine
potential
first
therapy
treatment
respiratory
diseases
combines
bronchodilator
activities
one
compound
company
evaluating
nebulized
ensifentrine
phase
clinical
program
enhance
ensifentrine
novel
inhaled
nebulized
copd
therapy
copd
maintenance
treatment
company
raised
gross
proceeds
million
private
placement
july
expects
funds
support
operations
phase
clinical
program
two
additional
formulations
ensifentrine
currently
phase
development
treatment
copd
dry
powder
inhaler
dpi
pressurized
inhaler
pmdi
ensifentrine
pilot
clinical
study
patients
hospitalized
potential
applications
cystic
fibrosis
asthma
respiratory
diseases
information
please
visit
